Ally Qiuling Ally Qiuling is a seasoned biostatistics professional currently serving as the Head of Biometrics at Hemab Therapeutics since 2025. Previously, Ally held the position of Head of Biostatistics at CRISPR Therapeutics from 2023 to 2025 and has extensive experience across various companies, including Alnylam Pharmaceuticals and Novartis Oncology. Ally earned a Ph.D. in Statistics from the University of Wisconsin-Madison and a B.S. in Mathematics from Nanjing University, supplemented by additional studies at the National University of Singapore.
This person is not in the org chart
This person is not in any teams
This person is not in any offices